Trial Profile
A Two-part, Randomized, Double-blind, Placebo Controlled, Ascending Dose Study to Assess the Safety and Tolerability of Single and Multiple Doses of Neumifil (a Novel Drug Candidate With Potential for Treatment of COVID-19)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Jan 2024
Price :
$35
*
At a glance
- Drugs Neumifil (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; First in man
- Sponsors Pneumagen
- 25 Jul 2022 Status changed from recruiting to completed.
- 12 May 2022 Results presented in a Pneumagen media release.
- 10 Nov 2021 According to a Pneumagen media release, the company announces the start of the study. Top line results from the study are expected in the first half of 2022.